• The Future of Psychedelics: A Discussion with Rick Doblin & Steven Levine

  • Sep 29 2021
  • Length: 1 hr and 4 mins
  • Podcast
The Future of Psychedelics: A Discussion with Rick Doblin & Steven Levine By cover art

The Future of Psychedelics: A Discussion with Rick Doblin & Steven Levine

Listen for free

View show details

  • Summary

  • In this episode, Dr. Jeffrey Lieberman is joined by pioneering psychedelics researchers, Drs. Rick Doblin and Steven Levine, to discuss the therapeutic applications of psychedelic drugs such as psilocybin, ketamine, LSD, MDMA, and ibogaine in treating mental health and addiction disorders, and the future path forward in legitimately harnessing their game changing potential.

    Dr. Rick Doblin is the Founder and Executive Director of MAPS (the Multidisciplinary Association for Psychedelic Studies), , a leading non-profit psychedelic drugs research and educational organization, with both domestic and international studies.

    Dr. Steven Levine is the Vice President of Patient Access at COMPASS Pathways, a leading psychedelics research organization conducting international clinical trials with psilocybin therapy for treatment-resistant depression. A pioneer in the clinical use of IV ketamine for treatment resistant depression, Dr. Levine is also the founder of Actify Neurotherapies, one of the largest networks of ketamine treatment centers in the US.

     
    Show more Show less
Show more Show less

What listeners say about The Future of Psychedelics: A Discussion with Rick Doblin & Steven Levine

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available